trending Market Intelligence /marketintelligence/en/news-insights/trending/XIf44jpdFLuPGH0yBUfB1g2 content esgSubNav
In This List

Boston Scientific acquires Neovasc's advanced biologic tissue capabilities

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Boston Scientific acquires Neovasc's advanced biologic tissue capabilities

Boston Scientific Corp. acquired certain manufacturing assets and capabilities of Neovasc Inc.'s advanced biological tissue business.

The company also made a 15% equity investment in Neovasc, acquiring 11,817,000 of Neovasc's common shares at 60 cents per share for $7.1 million. The shares were acquired for investment purposes.

Total consideration for both transactions was $75 million.

With the completion of the deal, Boston Scientific will integrate certain manufacturing assets and biologic tissue capabilities into its structural heart business for use in the manufacturing of the Lotus Valve System and future heart valve technologies.